A novel endogenous inhibitor for the treatment of diabetic nephropathy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1122176

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In various kidney diseases including the most common cause of end stage kidney disease, diabetic nephropathy, identifying the molecular mechanisms responsible for kidney failure are needed to assist in defining new targets and to develop more effective treatments. The proposed studies highlight the potential of a naturally occurring endogenous molecule called Lipoxin, as a modulator of kidney injury which may provide us with a novel approach to tackle the problem of diabetic nephropathy.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $774,606.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nephrology and Urology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

kidney disease | microrna | nephropathy | renal fibrosis | renal growth factors

Related Links